在早期使用中，曲妥珠单抗可作为以后的标准化化疗药物。
In early use, trastuzumab is approved for use following standard (adjuvant) chemotherapy.
HER2的异质性会影响HER 2阳性转移性乳腺癌患者曲妥珠单抗的效果和生存期。
HER2 Heterogeneity Affects Trastuzumab Responses and Survival in Patients With HER2-Positive Metastatic Breast Cancer.
和大多数治疗一样，曲妥珠单抗也有副作用，最常见的是轻度流感样症状，如寒战和发热。
Like most treatments, trastuzumab is associated with side-effects, the most common of which are mild flu-like symptoms, such as chills and fever during its administration.
分析该蛋白界定标准评判曲妥珠单抗耐药的灵敏度、特异度以及阳性预测值、阴性预测值。
We analyzed the sensibility, specificity, positive and negative predictive values of the SELDI-TOF-MS trastuzumab resistance standard.
我们调查了HER 2异质性对112例her 2阳性转移性乳腺癌患者的曲妥珠单抗疗效和临床预后的影响。
We investigated the impact of HER2 heterogeneity on trastuzumab responses and clinical outcomes in 112 patients with HER2-positive metastatic breast cancer.
曲妥珠单抗是一种人源化抗体，用于靶向和阻断her2的功能，而后者是由特异基因编码的一种蛋白，具有致癌潜能。
Trastuzumab is a humanised antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential.
曲妥珠单抗是一种人源化抗体，用于靶向和阻断her2的功能，而后者是由特异基因编码的一种蛋白，具有致癌潜能。
Trastuzumab is a humanised antibody, designed to target and block the function of HER2, a protein produced by a specific gene with cancer-causing potential.
应用推荐